Hypercholesterolemia
Conditions
Brief summary
Mean percent change from baseline in LDL-C at Day 56
Detailed description
Mean percent change from baseline in ApoB at Day 56, Mean percent change from baseline in non-HDL-C at Day 56, Mean percent change from baseline in Lp(a) at Day 56, Percentage of participants who at Day 56 have an LDL-C <70 mg/dL and ≥50% reduction from baseline, Percentage of participants who at Day 56 have an LDL-C<55 mg/dL and ≥50% reduction from baseline, Number of participants with ≥1 adverse event (AE), Number of participants discontinuing from study therapy due to AE
Interventions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean percent change from baseline in LDL-C at Day 56 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean percent change from baseline in ApoB at Day 56, Mean percent change from baseline in non-HDL-C at Day 56, Mean percent change from baseline in Lp(a) at Day 56, Percentage of participants who at Day 56 have an LDL-C <70 mg/dL and ≥50% reduction from baseline, Percentage of participants who at Day 56 have an LDL-C<55 mg/dL and ≥50% reduction from baseline, Number of participants with ≥1 adverse event (AE), Number of participants discontinuing from study therapy due to AE | — |
Countries
France, Spain
Outcome results
None listed